Chronic Myeloid Leukemia with cryptic Philadelphia translocation and extramedullary B-lymphoid blast phase as an initial presentation. 2018

Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
Department of Laboratory Medicine and Pathology, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha,Qatar. yassinmoha@gmail.com.

Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative neoplasm (MPN) characterized by the presence of a reciprocal translocation between the long arms of chromosomes 9 and 22, t(9;22)(q34:q11), resulting in fusion of the break point cluster region (BCR) with the ABL gene, which forms an oncogene, the transcript of which is an oncoprotein with a tyrosine kinase function. In the great majority of CML; BCR/ABL1 is cytogenetically visualized as t(9;22); giving rise to the Ph chromosome, harboring the chimeric gene. Cryptic or masked translocations occur in 2-10% patients with no evidence for the BCR/ABL rearrangement by conventional cytogenetics but are positive by Fluorescence in Situ Hybridization (FISH) and/or reverse transcriptase polymerase chain reaction (RT-PCR). These patients are described as Philadelphia negative (Ph negative) BCR/ABL1- positive CML with the chimeric gene present on the derivative chromosome 22, as in most CML cases, or alternatively on the derivative 9 in rare occasions. In the majority of cases, CML is diagnosed in the chronic phase; it is less frequently diagnosed in accelerated crises, and occasionally, its initial presentation is as acute leukemia. The prevalence of extramedullary blast phase (BP) has been reported to be 7-17% in patients with BP. Surprisingly, no extra-medullary blast crises of B- lymphoid lineage have been reported before among cases of CML as the initial presentation. We report an adult male diagnosed as CML- chronic phase when he was shortly presented with treatment-naive extramedullary B-lymphoid blast crises involving multiple lymph nodes, with no features of acceleration or blast crises in the peripheral blood (PB) and bone marrow (BM). In addition the patient had variant/cryptic Philadelphia translocation. This is the first report of CML, on the best of our knowledge, with extramedullary B-lymphoid blast phase, as initial presentation, that showed a cryptic Ph translocation.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010677 Philadelphia Chromosome An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE). Ph1 Chromosome,Ph 1 Chromosome,1 Chromosomes, Ph,Chromosome, Ph 1,Chromosome, Ph1,Chromosome, Philadelphia,Chromosomes, Ph 1,Chromosomes, Ph1,Ph 1 Chromosomes,Ph1 Chromosomes
D001752 Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. Blast Phase,Blast Crises,Blast Phases,Crises, Blast,Crisis, Blast,Phase, Blast,Phases, Blast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069439 Dasatinib A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB. (18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,BMS 354825,BMS-354825,BMS354825,N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide,Sprycel,354825, BMS

Related Publications

Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
April 2018, Experimental and molecular pathology,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
August 2015, Oncology (Williston Park, N.Y.),
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
August 2015, Oncology (Williston Park, N.Y.),
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
November 2023, Cureus,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
January 2013, Leukemia research reports,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
October 2022, International journal of molecular sciences,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
December 2022, Cureus,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
April 2022, Internal medicine (Tokyo, Japan),
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
June 2013, Blood research,
Dina S Soliman, and Aliaa M Amer, and Deena Mudawi, and Zafar Al-Sabbagh, and Einas Alkuwari, and Ahmad Al-Sabbagh, and Feryal Ibrahim, and Mohamed A Yassin
October 2016, The American journal of case reports,
Copied contents to your clipboard!